Abstract
The intent of this study was to optimise conditions for the use of 125 IUdR in the treatment of cancer. The radiopharmaceutical plus a biomodulator, methotrexate (MTX) was delivered by intra-tumoral injection of a thermosensitive hydrogel forming a slow release depot of 125 IUdR and MTX in the tumor. Methods: The C6 rat glioblastoma was implanted intra-cranially. A chitosan polymer was used to formulate a biodegradable and biocompatible implant for controlled intra-tumoral delivery of 125 IUdR plus MTX. Results: Intratumoral implant of hydrogel loaded with 7.0 -7.4 MBq of 125 IUdR resulted in survival of 20% of treated animals to 180 days after tumor implant. Simultaneous delivery of MTX increased the number of rats that were effectively cured, to 40%. Conclusion: Using an injectable thermolabile hydrogel as vehicle for 125 IUdR delivery a higher level of tumor control was achieved in a rat glioma model than had been previously reported.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.